Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 5, 2008, Pages 803-807

  Piantedosi, F V ^a   Caputo, F ^a   Mazzarella, G ^a   Gilli, M ^a   Pontillo, A ^a   D'Agostino, D ^a   Campbell, S ^b   Marsico, S A ^a   Bianco, A ^b  

^a AORN Monaldi   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

Chemotherapy; Gemcitabine; Ifosfamide; NSCLC; Paclitaxel; Platinum free

Indexed keywords

GEMCITABINE; IFOSFAMIDE; MESNA; PACLITAXEL;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 39749175580     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0537-1     Document Type: Article

References (23)

1. Belani CP, Fossella F (2005) Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 104(12):2766-2774
2. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern cooperative oncology group trial. J Clin Oncol 18:623-631
3. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367
4. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18:122-130
5. Non-small cell lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
6. Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087-1100
7. Pujol JL, Quantin X, Choma D, Jacot W, Khial F (2002) Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer. Lung Cancer 38(Suppl 3):S57-S60 Review
8. Recchia F, Saggio G, Cesta A, Candeloro G, Rea S (2005) Paclitaxel plus gemcitabine in advanced non-small cell lung cancer patients with low performance status. Anticancer Res 25(1B):409-414
9. Ichinose Y, Seto T, Semba H, Itoh K, Inoue Y, Tanaka F, Araki J, Tamanoi M, Yamamoto H, Iwamoto N (2005) UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer 93(7):770-773
10. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I (2001) Platinum-based and nonplatinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicentre trial. Lancet 357:1478-1484
11. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D (2005) Vinorelbine plus cisplatin vs docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937-2945
12. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21(16):3009-3010
13. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M for the Hellenic Cooperative Oncology Group (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578-3585
14. Smit E, van Meerbeeck J, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21:3909-3917
15. Baldini E, Ardizzoni A, Prochilo T, Cafferata MA, Boni L, Tibaldi C, Neumaier C, Conte PF, Rosso R (2001) Italian lung cancer task force. Gemcitabine, ifosfamide and navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC). Br J Cancer 85(10):1452-1455
16. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology: treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353
17. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926-2936
18. Le Chevalier T (1996) Single-agent activity of gemcitabine in advanced non-small cell lung cancer. Semin Oncol 23(5 Suppl 10):36-42
19. Kelly K (1999) The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer. Ann Oncol 10(Suppl 5):S53-S56
20. Eberhardt W, Niederle N (1992) Ifosfamide in non-small cell lung cancer: a review. Semin Oncol 19(Suppl 1):40-48
21. Hainsworth JD, Thompson DS, Greco FA (1995) Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13(7):1609-1614
22. Balducci L, Hardy CL, Lyman GH (2000) Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control 7(6):539-547
23. Balducci L (2000) Geriatric oncology: challenges for the new century. Eur J Cancer 36(14):1741-1754